AUTHORS
Derek Chan, MD, PhD, FRCPC, Fred Pluthero, PhD2, Maria Mansilla Pareja, PhD3, Walter Kahr, MD, PhD, FRCPC4, Yigal Dror, MD, FRCPC5
AFFILIATIONS
1 The Hospital for Sick Children, Toronto, Ontario, Canada
2 The Hospital for Sick Children, Toronto, Ontario, Canada
3 The Hospital for Sick Children, Toronto, Ontario, Canada
4 The Hospital for Sick Children, Toronto, Ontario, Canada
5 The Hospital for Sick Children, Toronto, Ontario, Canada
ABSTRACT
Congenital amegakaryocytic thrombocytopenia (CAMT) is an inherited bone marrow failure disorder caused by loss-of-function mutations affecting the thrombopoietin receptor (MPL) signalling axis critical to both megakaryopoiesis and hematopoietic stem and progenitor cell activity. Affected patients typically present in infancy with bleeding due to severe thrombocytopenia and subsequently progress to pancytopenic bone marrow failure during childhood with ongoing risks of transforming into hematopoietic malignancy. Hematopoietic stem cell transplantation remains the only established curative therapy for CAMT, but this treatment is associated with significant organ toxicities, high rates of graft failure and substantial transplant-related mortality. These limitations highlight an unmet clinical need to expand non-transplant treatment options for patients. To explore strategies for restoring MPL signalling in an affected pediatric patient with residual cell surface MPL expression, we performed primary bone marrow-derived hematopoietic and megakaryocytic colony-forming unit assays in the presence of (i) several transmembrane domain-targeted thrombopoietin receptor agonists (TPO-RAs), (ii) a previously described divalent single-chain variable fragment targeting MPL (TA136) and (iii) a small molecule inducer of megakaryopoiesis (DMAG) described to act in a thrombopoietin-independent manner. From these assays, we found that the second-generation TPO-RA Lusutrombopag significantly increased both primitive (CFU-GEMM) and megakaryocytic (CFU-Mk) colony formation with further synergistic enhancement observed in combination with the unfolded protein response modulator Azoramide. Complementary studies assessing MPL dimerization kinetics and downstream signalling activation in response to Lusutrombopag treatment remain ongoing. Translationally, this data provides functional proof-of-principle that select CAMT cases with residual cell surface MPL expression may be amenable to therapy with transmembrane domain-targeted TPO-RAs and provides a pre-clinical basis to support a future phase I single patient (n-of-1) clinical trial to evaluate Lusutrombopag as a novel treatment approach for this affected patient.
DISCLOSURES
Derek Chan, MD, PhD, FRCPC: No relevant conflicts of interest to declare.